Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Personalized Diagnostics Reimbursement: Sometimes A Hard Sell

This article was originally published in The Gray Sheet

Executive Summary

Two panelists at the AdvaMed 2007 meeting told different tales of gaining Medicare payment for their assays useful for personalized medicine

You may also be interested in...

AdvaMed Seeks Changes In CMS Payment Process For New Diagnostic Tests

Diagnostics manufacturers are urging CMS to use a more informed and transparent process to set payment rates for innovative tests

Monogram Launches Companion Diagnostic To Pfizer’s New HIV Drug

South San Francisco-based Monogram Biosciences launched its Trofile HIV diagnostic Aug. 6, timed with FDA approval of Pfizer's first-in-class HIV drug Selzentry (maraviroc) the same day

GemVax Aims For Alzheimer’s 'Game Changer' As Phase III Approaches

After announcing positive topline Phase II results for its Alzheimer’s candidate late last year, Korea's GemVax releases additional data showing significant improvement in secondary outcomes, further raising expectations for the novel peptide drug.




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts